Trending...
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Atos SE ("Atos" or the "Company") (OTC: AEXAY) investors concerning the Company and its officers' possible violations of federal securities laws.
On April 1, 2021, Atos issued a press release revealing that its auditors issued a "qualified opinion . . . as to two US legal entities representing 11% of 2020 consolidated revenue that require additional diligences." Specifically, the auditors identified "internal weaknesses over financial reporting process and revenue recognition in accordance with IFRS 15 leading to several accounting errors, as well as risk of override of controls in this respect." The Company stated that it had hired external firms to conduct an investigation and that, due to those procedures, the auditors had not been able to obtain sufficient evidence that the Company's financial statements were free of material misstatements within the necessary timeframe.
More on The PennZone
On this news, the Company's share price fell $1.67 per share, or 10.81%, to close at $13.78 per share on April 1, 2021, thereby injuring investors.
If you purchased Atos securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
On April 1, 2021, Atos issued a press release revealing that its auditors issued a "qualified opinion . . . as to two US legal entities representing 11% of 2020 consolidated revenue that require additional diligences." Specifically, the auditors identified "internal weaknesses over financial reporting process and revenue recognition in accordance with IFRS 15 leading to several accounting errors, as well as risk of override of controls in this respect." The Company stated that it had hired external firms to conduct an investigation and that, due to those procedures, the auditors had not been able to obtain sufficient evidence that the Company's financial statements were free of material misstatements within the necessary timeframe.
More on The PennZone
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
- Coach Bulinda Wright Advances To Top Five In National 'Top Host 2026 Competition'
On this news, the Company's share price fell $1.67 per share, or 10.81%, to close at $13.78 per share on April 1, 2021, thereby injuring investors.
If you purchased Atos securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- TrueDriveCost Launches Free Calculators for the Real Cost of Owning a Car
- A New Era Of Social Networking Is Here !
- Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
- HIRO Ostomy Belt Launch by Richard O'Hamill
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- The Well Woman Conference Comes To Philadelphia: A Powerful Experience Of Faith And Healing
- No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
- Pittsburgh Family Law Firm Pollock Begg Celebrates 16th Consecutive Best Law Firms Ranking
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- A Powerful Encounter Awaits Philadelphia: Dr. Mattie Nottage Joins Brother Marcus on Air
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- Beyond Spots & Dots Spreads Holiday Cheer at Old Economy Village's Festival of Trees
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- AI Trading Agents Analyze Pharmaceutical Stocks as Biotech Innovation Draws Attention (LLY, GILD, BSX, AZN, ABBV, MRNA)